Sort   by:  
 Page size 
UnknownAspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Not available
S-EPMC10758705 | biostudies-literature
UnknownDifferential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
Not available
S-EPMC5394924 | biostudies-literature
UnknownTelomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
Not available
S-EPMC6535646 | biostudies-literature
UnknownPhase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Not available
S-EPMC5665563 | biostudies-literature
UnknownActive oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Not available
S-EPMC2686135 | biostudies-literature
UnknownA phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Not available
S-EPMC4803139 | biostudies-literature
UnknownCD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Not available
S-EPMC5773411 | biostudies-literature
UnknownDetection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements.
Not available
S-EPMC11524540 | biostudies-literature
UnknownComparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Not available
S-EPMC4751065 | biostudies-literature
UnknownOTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
Not available
S-EPMC7930094 | biostudies-literature
Sort   by:  
 Page size